EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia

Alice Mims, Zhuoer Xie, Ravi Potluri, David Rotter, Manoj Chevli, Thomas Prebet, Lona Gaugler, Maria Strocchia, Alberto Vasconcelos, Jan Sieluk iD

Leukemia & Lymphoma · 2025

DOI: 10.1080/10428194.2024.2425792 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Leukemia & Lymphoma, 2025. Verfasst von Alice Mims und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ohio State University, Columbus, OH, USA. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral azacitidine (Oral-AZA) is recommended as maintenance therapy for patients with newly diagnosed acute myeloid leukemia (ND AML) achieving remission with intensive chemotherapy (IC) but not transplant candidates; venetoclax plus injectable azacitidine (VEN-AZA) is recommended for patients ineligible for IC. Some patients may be considered candidates for either regimen. This retrospective study used Flatiron Health's database to compare treatment patterns and clinical outcomes with Oral-AZA maintenance after IC (IC🡪Oral-AZA) versus frontline VEN-AZA. Relapse-free survival (RFS) and overall survival (OS) were analyzed at 4 different time points, including from Oral-AZA initiation (IC🡪Oral-AZA cohort) or from remission (VEN-AZA cohort) in the Core Analysis. Median RFS was 14.9 and 8.1 months for IC🡪Oral-AZA and VEN-AZA propensity score-matched cohorts, in the Core Analysis (n = 32 in each; p = 0.027); median OS was 18.7 and 15.2 months (p = 0.034). In patients with AML, IC🡪Oral-AZA significantly improved RFS and OS compared with VEN-AZA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedBridged Bicyclo Compounds, HeterocyclicSulfonamidesMiddle AgedRetrospective StudiesAdministration, OralTreatment OutcomeAdultAged, 80 and over

Stichwörter der Autor:innen

Acute myeloid leukemiahealth outcomes researchoral azacitidinereal-world evidence

Substanzen

AzacitidinevenetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Ohio State University, Columbus, OH, USA.
  • Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
  • Putnam Associates, New York, NY, USA.
  • Bristol Myers Squibb, Uxbridge, UK.
  • Bristol Myers Squibb, Princeton, NJ, USA.

ORCID-Profile: Jan Sieluk

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Mims, A., Xie, Z., Potluri, R., Rotter, D., Chevli, M., Prebet, T., Gaugler, L., Strocchia, M., Vasconcelos, A., & Sieluk, J. (2025). Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma. https://doi.org/10.1080/10428194.2024.2425792

Vancouver

Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, et al. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma. 2025. doi:10.1080/10428194.2024.2425792

BibTeX
@article{Mims2025,
  author = {Mims, Alice and Xie, Zhuoer and Potluri, Ravi and Rotter, David and Chevli, Manoj and Prebet, Thomas and Gaugler, Lona and Strocchia, Maria and Vasconcelos, Alberto and Sieluk, Jan},
  title = {Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia},
  journal = {Leukemia & Lymphoma},
  year = {2025},
  doi = {10.1080/10428194.2024.2425792}
}
Kostenlos starten →